Table 1 Multivariable Cox proportional hazards analysis of risk factors for postoperative RT biochemical failure, clinical metastasis and prostate cancer-specific mortality

From: Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality

Post-radiotherapy BCR

 

TJU

 

HR

95% Cl

P-value

NRP1

2.30

1.14–4.62

0.019

GS<8

0.53

0.12–2.40

0.410

GS≥8

2.85

1.46–5.57

0.002

Lymph node involvement

1.55

0.20–12.27

0.676

Positive surgical margin

0.95

0.45–2.00

0.897

Extra-capsular extension

1.67

0.62–4.54

0.311

Seminal vesicle invasion

1.38

0.71–2.67

0.344

Pre-operative PSA 10–20 ng/ml

1.59

0.69–3.66

0.275

Pre-operative PSA >20 ng/ml

1.64

0.69–3.92

0.261

Metastasis

 

Mayo Clinic

 

HR

95% Cl

P-value

NRP1

1.73

1.15–2.59

0.008

GS<8

0.36

0.13–0.82

0.026

GS⩾8

3.49

2.31–5.30

<0.0001

Lymph node involvement

1.50

0.82–2.76

0.194

Positive surgical margin

0.93

0.61–1.39

0.714

Extra-capsular extension

1.31

0.86–1.99

0.210

Seminal vesicle invasion

1.57

0.98–2.50

0.060

Pre-operative PSA 10–20 ng/ml

0.73

0.44–1.22

0.237

Pre-operative PSA >20 ng/ml

0.80

0.47–1.34

0.392

 

JHMI post-RP

 

HR

95% Cl

P-value

NRP1

1.91

1.01–3.61

0.048

GS<8

NA

NA

NA

GS⩾8

4.26

2.25–8.08

<0.0001

Lymph node involvement

3.05

1.49–6.25

0.002

Positive surgical margin

1.05

0.53–2.09

0.894

Extra-capsular extension

2.28

1.01–5.15

0.048

Seminal vesicle invasion

2.40

1.20–4.78

0.013

Pre-operative PSA 10–20 ng/ml

1.87

0.93–3.76

0.081

Pre-operative PSA >20 ng/ml

1.11

0.41–3.01

0.840

Prostate cancer-specific mortality

 

Mayo Clinic

 

HR

95% Cl

P-value

NRP1

1.83

1.14–2.98

0.013

GS<8

0.71

0.20–1.94

0.540

GS⩾8

3.52

2.18–5.75

<0.0001

Lymph node involvement

2.33

1.26–4.32

0.007

Positive surgical margin

1.42

0.89–2.29

0.141

Extra-capsular extension

1.46

0.89–2.39

0.131

Seminal vesicle invasion

2.14

1.28–3.59

<0.0001

Pre-operative PSA 10–20 ng/ml

0.82

0.45–1.46

0.500

Pre-operative PSA >20 ng/ml

0.61

0.33–1.10

0.105

 

JHMI post-BCR

 

HR

95% Cl

P-value

NRP1

2.01

1.05–3.85

0.034

GS<8

NA

NA

NA

GS⩾8

4.53

2.28–9.01

<0.0001

Lymph node involvement

0.97

0.45–2.08

0.930

Positive surgical margin

0.54

0.26–1.11

0.094

Extra-capsular extension

0.77

0.32–1.83

0.552

Seminal vesicle invasion

2.74

1.25–5.98

0.012

Pre-operative PSA 10–20 ng/ml

1.04

0.50–2.16

0.925

Pre-operative PSA >20 ng/ml

1.03

0.37–2.90

0.955

  1. Abbreviations: BCR, biochemical recurrence; CI, confidence interval; GS, Gleason score; HR, hazard ratio; JHMI, Johns Hopkins Medical Institutions; NA, not applicable; NRP1, neuropilin-1; PSA, prostate specific antigen; RT, radiation therapy; TJU, Thomas Jefferson University. Bold values indicate P<0.05.
Back to article page